Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Royalty Pharma plcRPRX · Entity 3100 | EVP, Investments & CLO | December 17, 2025 | December 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Royalty Pharma plc
Report date December 17, 2025 · Filed December 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy GWL 2014 G, LLC | 30,654 |
Reported balance
After 2025-12-17 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-12-17 · Sale · Disposed 79,346 · Balance 30,654 F1: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.31 to $38.87 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy GWL 2014 G, LLC | 0 |
Reported balance
After 2025-12-18 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-12-18 · Sale · Disposed 30,654 · Balance 0 F1: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.31 to $38.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy GWL 2013 NG, LLC | 495,860 |
Reported balance
Holding disclosure · report date 2025-12-17 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 495,860 |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy IRA | 273,960 |
Reported balance
Holding disclosure · report date 2025-12-17 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 273,960 |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy GWL 2023 G HoldCo LLC | 6,084 |
Reported balance
Holding disclosure · report date 2025-12-17 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 6,084 |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy Spouse | 4,011.19 |
Reported balance
Holding disclosure · report date 2025-12-17 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 4,011.19 |
Filing footnotes · ownership attribution and instrument terms
F1: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.31 to $38.87 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.31 to $38.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2025 Filed Dec 19, 2025 17:24 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 30,654 | $38.50 | $1,180,053.32 |
DisclosureSEC source: 0001814899-25-000010 · wk-form4_1766183086.xml · nonDerivative · entry 2 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: Plan reported Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 0 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.31 to $38.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 17:24 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 79,346 | $38.57 | $3,060,280.00 |
DisclosureSEC source: 0001814899-25-000010 · wk-form4_1766183086.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: Plan reported Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 30,654 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.31 to $38.87 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 17:01 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 110,000 | $39.77 | $4,375,008.00 |
DisclosureSEC source: 0001814899-25-000008 · wk-form4_1764972084.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: Plan reported Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 110,000 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.36 to $40.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 16:55 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 230 | $39.03 | $8,977.61 |
DisclosureSEC source: 0001814899-25-000006 · wk-form4_1763762134.xml · nonDerivative · entry 8 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.79 to $39.34 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 16:55 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 2,770 | $38.29 | $106,051.67 |
DisclosureSEC source: 0001814899-25-000006 · wk-form4_1763762134.xml · nonDerivative · entry 7 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 230 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.79 to $38.78 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 16:55 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 2,470 | $39.01 | $96,346.55 |
DisclosureSEC source: 0001814899-25-000006 · wk-form4_1763762134.xml · nonDerivative · entry 6 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: Plan reported Ownership: Indirect · By GWL 2021 G, LLC Disclosed balance after: 0 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $39.34 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 16:55 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 25,530 | $38.28 | $977,260.32 |
DisclosureSEC source: 0001814899-25-000006 · wk-form4_1763762134.xml · nonDerivative · entry 5 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: Plan reported Ownership: Indirect · By GWL 2021 G, LLC Disclosed balance after: 2,470 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.77 to $38.76 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 16:55 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 4,599 | $39.01 | $179,393.65 |
DisclosureSEC source: 0001814899-25-000006 · wk-form4_1763762134.xml · nonDerivative · entry 4 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: Plan reported Ownership: Indirect · By GWL 2020 G, LLC Disclosed balance after: 0 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $39.34 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 16:55 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 47,401 | $38.28 | $1,814,448.66 |
DisclosureSEC source: 0001814899-25-000006 · wk-form4_1763762134.xml · nonDerivative · entry 3 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: Plan reported Ownership: Indirect · By GWL 2020 G, LLC Disclosed balance after: 4,599 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.77 to $38.76 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 16:55 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 4,628 | $39.01 | $180,527.64 |
DisclosureSEC source: 0001814899-25-000006 · wk-form4_1763762134.xml · nonDerivative · entry 2 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: Plan reported Ownership: Indirect · By GWL 2023 G HoldCo LLC Disclosed balance after: 6,084 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $39.34 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 16:55 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 47,798 | $38.28 | $1,829,650.08 |
DisclosureSEC source: 0001814899-25-000006 · wk-form4_1763762134.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: Plan reported Ownership: Indirect · By GWL 2023 G HoldCo LLC Disclosed balance after: 10,712 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.77 to $38.76 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 16:18 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 6,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001814899-25-000003 · wk-form4_1762550308.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: No plan indicated Ownership: Indirect · By GWL 2023 G HoldCo LLC Disclosed balance after: 58,510 F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards. Read SEC document |
| August 08, 2025 Filed Aug 8, 2025 16:56 UTC | Royalty Pharma plc RPRX · Entity 3100 | GiftLP interests in RPI US Partners 2019, LP · Derivative | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001802768-25-000103 · wk-form4_1754686616.xml · derivative · entry 9 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 85,000 shares Expires not disclosed F2 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with an exchange. F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 16:56 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 3,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001802768-25-000103 · wk-form4_1754686616.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: No plan indicated Ownership: Indirect · By GWL 2023 G HoldCo LLC Disclosed balance after: 52,342 F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards. Read SEC document |
| May 16, 2025 Filed May 20, 2025 16:51 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass E Ordinary Shares · Derivative | 1,944,471 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001802768-25-000065 · wk-form4_1747774253.xml · derivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1)(2) Disclosed balance after: 1,944,471 Underlying: Class A Ordinary Shares · 1,944,471 shares Expires not disclosed F1 · shares: Reflects the exempt indirect acquisition by the Reporting Person pursuant to Rule 16b-3 of Class E ordinary shares ("Class E Shares") of Royalty Pharma Holdings Ltd ("RPH") in connection with the consummation of the transactions contemplated by the Membership Interests Purchase Agreement, dated as of January 10, 2025 (as many be amended from time to time, the "Purchase Agreement") between RPH, Royalty Pharma, LLC, RP Management, LLC, the Issuer and certain other parties thereto. F2 · derivative.exercise_date: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion. F2 · derivative.expiration_date: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion. F2 · derivative.underlying_shares: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion. F2 · balance_after: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion. Read SEC document |
| May 08, 2025 Filed May 9, 2025 17:15 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 48,646 | $0.00 | $0.00 |
DisclosureSEC source: 0001802768-25-000037 · wk-form4_1746825335.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: No plan indicated Ownership: Indirect · By GWL 2023 G HoldCo LLC Disclosed balance after: 48,646 F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards. Read SEC document |
| August 12, 2024 Filed Aug 12, 2024 19:19 UTC | Royalty Pharma plc RPRX · Entity 3100 | GiftLP interests in RPI US Partners 2019, LP · Derivative | 7,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001802768-24-000049 · wk-form4_1723504736.xml · derivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 79,200 shares Expires not disclosed F1 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange. F2 · kind: The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold. F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. Read SEC document |
| November 13, 2023 Filed Nov 14, 2023 19:35 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionLP interests in RPI US Partners 2019, LP · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001802768-23-000032 · wk-form4_1700008499.xml · derivative · entry 8 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: No plan indicated Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 162,680 Underlying: Class A Ordinary Shares · 100,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F2 · balance_after: The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 4,573,096 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances. Read SEC document |
| November 13, 2023 Filed Nov 14, 2023 19:35 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionLP interests in RPI US Partners 2019, LP · Derivative | 5,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001802768-23-000032 · wk-form4_1700008499.xml · derivative · entry 7 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: No plan indicated Ownership: Indirect · By GWL 2020 G, LLC Disclosed balance after: 245,299 Underlying: Class A Ordinary Shares · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F2 · balance_after: The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 4,573,096 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances. Read SEC document |
| November 13, 2023 Filed Nov 14, 2023 19:35 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionClass A Ordinary Shares | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001802768-23-000032 · wk-form4_1700008499.xml · nonDerivative · entry 2 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: No plan indicated Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 220,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F1 · price: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F2 · balance_after: The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 4,573,096 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances. Read SEC document |
| November 13, 2023 Filed Nov 14, 2023 19:35 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionClass A Ordinary Shares | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001802768-23-000032 · wk-form4_1700008499.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: No plan indicated Ownership: Indirect · By GWL 2020 G, LLC Disclosed balance after: 80,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F1 · price: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F2 · balance_after: The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 4,573,096 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances. Read SEC document |
| August 08, 2023 Filed Aug 8, 2023 17:36 UTC | Royalty Pharma plc RPRX · Entity 3100 | GiftLP interests in RPI US Partners 2019, LP · Derivative | 5,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-045063 · doc4.xml · derivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 55,550 shares Expires not disclosed F1 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange. F2 · kind: The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold. F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. Read SEC document |
| June 06, 2023 Filed Jun 6, 2023 17:07 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 79,099 | $33.82 | $2,674,795.96 |
DisclosureSEC source: 0001209191-23-034792 · doc4.xml · nonDerivative · entry 4 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: No plan indicated Ownership: Indirect · By GWL 2020 G, LLC Disclosed balance after: 30,000 F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $34.02 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 05, 2023 Filed Jun 6, 2023 17:07 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 19,215 | $33.54 | $644,446.12 |
DisclosureSEC source: 0001209191-23-034792 · doc4.xml · nonDerivative · entry 3 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: No plan indicated Ownership: Indirect · By GWL 2020 G, LLC Disclosed balance after: 109,099 F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $33.69 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 17:07 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 1,686 | $33.54 | $56,542.03 |
DisclosureSEC source: 0001209191-23-034792 · doc4.xml · nonDerivative · entry 2 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: No plan indicated Ownership: Indirect · By GWL 2020 G, LLC Disclosed balance after: 128,314 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.53 to $33.55 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 17:07 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 92,221 | $33.65 | $3,102,803.21 |
DisclosureSEC source: 0001209191-23-034792 · doc4.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: No plan indicated Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 120,000 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.51 to $33.80 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 29, 2023 Filed Mar 30, 2023 17:52 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 12,779 | $37.03 | $473,165.48 |
DisclosureSEC source: 0001209191-23-021648 · doc4.xml · nonDerivative · entry 2 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: No plan indicated Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 212,221 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.75 to $37.31 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 28, 2023 Filed Mar 30, 2023 17:52 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 100,000 | $37.06 | $3,706,130.00 |
DisclosureSEC source: 0001209191-23-021648 · doc4.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: No plan indicated Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 225,000 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.90 to $37.19 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 19:14 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 25,000 | $37.27 | $931,657.50 |
DisclosureSEC source: 0001209191-23-013398 · doc4.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 325,000 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.19 to $37.37 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 22, 2022 Filed Nov 22, 2022 17:29 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 1,900 | $43.14 | $81,969.04 |
DisclosureSEC source: 0001209191-22-058450 · doc4.xml · nonDerivative · entry 4 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 350,000 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.30 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 22, 2022 Filed Nov 22, 2022 17:29 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 14,469 | $43.19 | $624,878.49 |
DisclosureSEC source: 0001209191-22-058450 · doc4.xml · nonDerivative · entry 3 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2020 G, LLC Disclosed balance after: 130,000 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.30 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 17:29 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 3,100 | $43.11 | $133,637.90 |
DisclosureSEC source: 0001209191-22-058450 · doc4.xml · nonDerivative · entry 2 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 351,900 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.20 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 17:29 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 20,531 | $43.11 | $885,081.14 |
DisclosureSEC source: 0001209191-22-058450 · doc4.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2020 G, LLC Disclosed balance after: 144,469 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.20 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 17:13 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 25,000 | $43.85 | $1,096,287.50 |
DisclosureSEC source: 0001209191-22-056677 · doc4.xml · nonDerivative · entry 2 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 355,000 F1 · shares: Class A Ordinary Shares sold pursuant to a 10b5-1 plan. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.65 to $43.94 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 17:13 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 25,000 | $43.85 | $1,096,325.00 |
DisclosureSEC source: 0001209191-22-056677 · doc4.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2020 G, LLC Disclosed balance after: 165,000 F1 · shares: Class A Ordinary Shares sold pursuant to a 10b5-1 plan. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.64 to $43.95 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2022 Filed Nov 14, 2022 17:13 UTC | Royalty Pharma plc RPRX · Entity 3100 | GiftLP interests in RPI US Partners 2019, LP · Derivative | 5,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-056677 · doc4.xml · derivative · entry 7 Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 58,890 shares Expires not disclosed F4 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange. F5 · kind: The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold. F6 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F6 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. Read SEC document |
| August 10, 2022 Filed Aug 11, 2022 17:02 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 8,995 | $43.93 | $395,108.07 |
DisclosureSEC source: 0001209191-22-045451 · doc4.xml · nonDerivative · entry 2 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2020 G, LLC Disclosed balance after: 201,114 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.90 to $44.01 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 17:02 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 11,859 | $43.92 | $520,801.03 |
DisclosureSEC source: 0001209191-22-045451 · doc4.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2020 G, LLC Disclosed balance after: 210,109 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.90 to $43.95 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 17:01 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 4,046 | $43.97 | $177,892.91 |
DisclosureSEC source: 0001209191-22-043689 · doc4.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2020 G, LLC Disclosed balance after: 221,968 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.91 to $44.01 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 27, 2022 Filed Jul 27, 2022 18:20 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 100 | $43.90 | $4,390.00 |
DisclosureSEC source: 0001209191-22-043286 · doc4.xml · nonDerivative · entry 6 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2020 G, LLC Disclosed balance after: 226,014 Read SEC document |
| July 27, 2022 Filed Jul 27, 2022 18:20 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 25,000 | $43.76 | $1,094,055.00 |
DisclosureSEC source: 0001209191-22-043286 · doc4.xml · nonDerivative · entry 5 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 380,000 F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.70 to $43.89 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 26, 2022 Filed Jul 27, 2022 18:20 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 13,886 | $43.12 | $598,824.03 |
DisclosureSEC source: 0001209191-22-043286 · doc4.xml · nonDerivative · entry 4 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2020 G, LLC Disclosed balance after: 226,114 F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.93 to $43.35 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 26, 2022 Filed Jul 27, 2022 18:20 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 5,443 | $43.03 | $234,222.63 |
DisclosureSEC source: 0001209191-22-043286 · doc4.xml · nonDerivative · entry 3 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 405,000 F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.91 to $43.13 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 18:20 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 11,114 | $42.98 | $477,641.93 |
DisclosureSEC source: 0001209191-22-043286 · doc4.xml · nonDerivative · entry 2 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2020 G, LLC Disclosed balance after: 228,886 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.90 to $43.17 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 18:20 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 19,557 | $42.90 | $839,065.71 |
DisclosureSEC source: 0001209191-22-043286 · doc4.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 410,443 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.72 to $43.16 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 27, 2022 Filed May 31, 2022 17:19 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 13,974 | $40.77 | $569,753.52 |
DisclosureSEC source: 0001209191-22-032900 · doc4.xml · nonDerivative · entry 2 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 430,000 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.67 to $40.89 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 26, 2022 Filed May 31, 2022 17:19 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 86,026 | $40.21 | $3,459,337.73 |
DisclosureSEC source: 0001209191-22-032900 · doc4.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 443,974 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.26 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 23, 2022 Filed May 25, 2022 17:10 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 100,000 | $40.27 | $4,026,770.00 |
DisclosureSEC source: 0001209191-22-031924 · doc4.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 530,000 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.80 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 17, 2021 Filed Nov 18, 2021 19:18 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 84,148 | $42.39 | $3,566,831.76 |
DisclosureSEC source: 0001209191-21-065639 · doc4.xml · nonDerivative · entry 4 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 630,000 F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.92 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 19:18 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 65,852 | $42.12 | $2,773,659.90 |
DisclosureSEC source: 0001209191-21-065639 · doc4.xml · nonDerivative · entry 3 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 714,148 F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.29 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.